138 related articles for article (PubMed ID: 38775006)
1. Cytokine/Antibody Fusion Protein Design and Evaluation.
Fabilane CS; Stephenson AC; Leonard EK; VanDyke D; Spangler JB
Curr Protoc; 2024 May; 4(5):e1061. PubMed ID: 38775006
[TBL] [Abstract][Full Text] [Related]
2. A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity.
Gillies SD
Protein Eng Des Sel; 2013 Oct; 26(10):561-9. PubMed ID: 24025193
[TBL] [Abstract][Full Text] [Related]
3. The present and future of immunocytokines for cancer treatment.
Gout DY; Groen LS; van Egmond M
Cell Mol Life Sci; 2022 Sep; 79(10):509. PubMed ID: 36066630
[TBL] [Abstract][Full Text] [Related]
4. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.
Sommavilla R; Pasche N; Trachsel E; Giovannoni L; Roesli C; Villa A; Neri D; Kaspar M
Protein Eng Des Sel; 2010 Aug; 23(8):653-61. PubMed ID: 20551083
[TBL] [Abstract][Full Text] [Related]
5. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
6. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.
Tzeng A; Kwan BH; Opel CF; Navaratna T; Wittrup KD
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3320-5. PubMed ID: 25733854
[TBL] [Abstract][Full Text] [Related]
7. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
8. Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity.
Leonard EK; Tomala J; Gould JR; Leff MI; Lin JX; Li P; Porter MJ; Johansen ER; Thompson L; Cao SD; Henclova T; Huliciak M; Vaněk O; Kovar M; Leonard WJ; Spangler JB
bioRxiv; 2023 May; ():. PubMed ID: 37205604
[TBL] [Abstract][Full Text] [Related]
9. Inference of molecular structure for characterization and improvement of clinical grade immunocytokines.
Ongaro T; Guarino SR; Scietti L; Palamini M; Wulhfard S; Neri D; Villa A; Forneris F
J Struct Biol; 2021 Mar; 213(1):107696. PubMed ID: 33493635
[TBL] [Abstract][Full Text] [Related]
10. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
Front Immunol; 2020; 11():832. PubMed ID: 32457754
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
Neri D
Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
[TBL] [Abstract][Full Text] [Related]
12. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
Hutmacher C; Neri D
Adv Drug Deliv Rev; 2019 Feb; 141():67-91. PubMed ID: 30201522
[TBL] [Abstract][Full Text] [Related]
13. A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties.
Winter J; Barbin K; Bacci C; Bunte T
J Pharm Biomed Anal; 2011 Jan; 54(1):81-6. PubMed ID: 20828971
[TBL] [Abstract][Full Text] [Related]
14. [Immunotoxins and immunocytokines].
Contet A; Caussanel V; Beck A; Lowe P
Med Sci (Paris); 2019 Dec; 35(12):1054-1061. PubMed ID: 31903917
[TBL] [Abstract][Full Text] [Related]
15. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
[TBL] [Abstract][Full Text] [Related]
16. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
17. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
[TBL] [Abstract][Full Text] [Related]
18. Utilizing Immunocytokines for Cancer Therapy.
Runbeck E; Crescioli S; Karagiannis SN; Papa S
Antibodies (Basel); 2021 Mar; 10(1):. PubMed ID: 33803078
[TBL] [Abstract][Full Text] [Related]
19. Designing cell-targeted therapeutic proteins reveals the interplay between domain connectivity and cell binding.
Robinson-Mosher A; Chen JH; Way J; Silver PA
Biophys J; 2014 Nov; 107(10):2456-66. PubMed ID: 25418314
[TBL] [Abstract][Full Text] [Related]
20. Immunocytokines: amplification of anti-cancer immunity.
Davis CB; Gillies SD
Cancer Immunol Immunother; 2003 May; 52(5):297-308. PubMed ID: 12700945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
